ABSTRACT
A pitiríase liquenóide e varioliforme aguda (PLEVA), é classificada dentro do grupo de dermatoses crônicas, idiopáticas, chamado de "parapsoríases". Caracteriza-se por erupção aguda ou subaguda de múltiplas e pequenas pápulas eritematosas, que podem evoluir com vesiculação e necrose hemorrágica central. A fototerapia possui altos níveis de eficácia e tolerabilidade em uma variedade de doenças inflamatórias e neoplásicas da pele caracterizadas por infiltrados epiteliais e dérmicos rico em linfócitos T . Este artigo relata o caso de uma mulher de meia idade com apresentação clínica típica e diagnóstico histopatológico de PLEVA. Por se tratar de doença que nem sempre responde a tratamentos sistêmicos, o objetivo da proposta terapêutica com fototerapia visou suprimir a doença por seu efeito anti-inflamatório e imunossupressor e prevenir a evolução para o linfoma cutâneo de células T.
Pityriasis lichenoid et varioliformis acute (PLEVA) is classified within the group of chronic, idiopathic dermatoses called "parapsoriasis". It is characterized by an acute or subacute eruption of multiple small erythematous papules, which may progress to vesiculation and central hemorrhagic necrosis. Phototherapy has high levels of efficacy and tolerability in a variety of inflammatory and neoplastic skin diseases characterized by epithelial and dermal infiltrates rich in T lymphocytes. This article reports the case of a middle-aged woman with typical clinical presentation and histopathological diagnosis of PLEVA. As it is a disease that does not always respond to systemic treatments, the objective of the therapeutic proposal with phototherapy was to suppress the disease due to its anti-inflammatory and immunosuppressive effect and prevent the evolution to cutaneous T-cell lymphoma.
ABSTRACT
Epithelial cell adhesion molecule (EpCAM) has been used as diagnostic/prognostic marker and therapeutic target. The aim of the present study was to compare immunoreactivity of antibodies against distinct epitopes in the ectodomain of EpCAM for detection of carcinoma from different primary sites and of different histological types in effusions and peritoneal wash. Two antibodies against epitopes in the EGF-like domain I (clones Moc-31 and Ber-EP4) and one antibody against the epitope in the cysteine-poor region (158210) of EpCAM were used (all commercially available). Independently of the clone used, EpCAM overexpression was observed in almost all samples when all the adenocarcinoma samples were analyzed together. By using Moc-31, EpCAM overexpression was observed in all samples of adenocarcinoma. Absence of EpCAM overexpression was observed in a few adenocarcinoma samples at some sites of tumor origin, including ovary, breast and stomach, when Ber-EP4 and 158210 were used. Regarding carcinomas aside from adenocarcinomas, histological types, such as squamous cell, urothelial and small cell carcinoma showed different degrees of EpCAM expression according to the antibody used. In squamous cell carcinoma, overexpression was observed only with the clone 158210. It was concluded that, overall, most samples of metastatic carcinoma from effusions showed overexpression of EpCAM. However, there are significant variations in its detection according to the primary site, histological type of the carcinoma and depending on the antibody used. Thus, the use of more than one type of anti-EpCAM antibody would increase the chance of its detection in metastatic carcinoma effusion.
